Trials
1 active
4 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)”In the company’s words, NCT06440525 on ClinicalTrials.gov
- Tested for
- Primary Sjögren Syndrome
- Main trialPhase 2
- “The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are: * Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain? * Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's? * What are the blood levels of RSLV-132 over time? * What is the immune (antibody) response in the body to RSLV-132? * What is the safety profile of RSLV-132? Researchers will compare RSLV-132 to a placebo (a look-alike substance that contains no…”In the company’s words, NCT06440525 on ClinicalTrials.gov
Other drugs for Primary Sjögren Syndrome
- NipocalimabJohnson & Johnson (Janssen) · Phase 3
- TelitaciceptVor Biopharma · Phase 3
- IanalumabNovartis · Phase 3
- DazodalibepAmgen · Phase 3
- DeucravacitinibBristol Myers Squibb · Phase 3
- RhPRG4Lubris Bio Pty Ltd · Phase 2
Coming up1
- 1 May 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 1 May 2027 | A Study of RSLV-132 in Females With Sjögren's Disease | |
| Phase 2Completed | 15 Jul 2018 | A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome | |
| Phase 2Completed | 28 May 2020 | A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) | |
| Phase 2Completed | 31 Oct 2023 | Phase 2 Study of RSLV-132 in Subjects With Long COVID |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026